Journal article
Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis
C Arana Yi, CS Tam, S Verstovsek
Future Oncology | FUTURE MEDICINE LTD | Published : 2015
DOI: 10.2217/fon.14.272
Abstract
The JAK1 and JAK2 inhibitor ruxolitinib has approved indications in myelofibrosis, a BCR-AB1-negative myeloproliferative neoplasm associated with progressive bone marrow fibrosis and shortened survival. In Phase III clinical studies, ruxolitinib provided rapid and durable improvement of myelofibrosis-related splenomegaly and symptoms irrespective of mutation status, and was associated with a survival advantage compared with placebo or best available therapy. Because of dose-dependent cytopenias, blood count monitoring and dose titration are important to optimize therapy. Specific precautions apply to the treatment of patients with or at risk of serious infections. Discontinuation of ruxoliti..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
CS Tam recieved honorarium from Novartis. S Verstovsek received research funding from Incyte, AstraZeneca, Lilly Oncology, Geron, NS Pharma, Bristol-Myers Squibb, Novartis, Celgene, Gilead, Seattle Genetics, Promedior and Cell Therapeutics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.Medical writing assistance was provided by Roland Tacke, PhD, CMPP, of Evidence Scientific Solutions and funded by Incyte Corporation.